Track market-moving stories before they get noisy

NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.

New evidence highlights the power of Natera’s latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrated an industry-leading analytical limit of detection (LOD95) below 1 part per million (ppm), and detection observed significantly below 1 part per 10 million.1

Spanning tumor types and treatment modalities, multiple ESMO presentations will show that serial ctDNA testing provides meaningful clinical benefit:

ICONIC trial in gastroesophageal cancer (abstract 2901P): Among patients treated with perioperative chemotherapy and immunotherapy, MRD clearance during neoadjuvant therapy was strongly associated with a lower risk of recurrence and a favorable pathologic response. Signatera Genome with Phased and Structural Variants detected all evaluable recurrences during surveillance, with a >7.3 month median lead time over standard imaging.SAGITTARIUS trial in colon cancer (abstract 808P): In this phase III trial, post-operative patients were randomized to a physician-choice adjuvant treatment plan prior to receiving MRD results to assess impact. The analysis showed that Signatera results influenced a change to providers’ pre-planned treatment for one in three patients, of which 87% were treatment de-escalated based on MRD negativity.Colorectal/Breast cancer (abstract 4258P): In a retrospective analysis of surveillance monitoring of stage I-III breast and colorectal cancer survivors, serial Signatera negativity was associated with an extremely low 2-year recurrence risk, which may help refine risk stratification and inform eligibility for solid organ transplant earlier than current methodologies.Breast cancer (abstract 1770RO): In HER2+ metastatic breast cancer, an analysis of exceptional responders on anti-HER2 therapy showed 81% with sustained MRD-negativity during serial monitoring, supporting the potential for Signatera-guided de-escalation.MDT-Bridge trial in non-small cell lung cancer (NSCLC) (abstract LBA62): This phase II trial evaluated MRD clearance from baseline to pre-surgery/pre-CRT using the Clarity™ assay with phased variant technology.MRD-guided reflex to liquid CGP drives actionable treatment decisions (abstract 4260P): In a cohort of 50 patients across 10 tumor types, Signatera, complemented by reflex to blood-based comprehensive genomic profiling (liquid CGP), identified clinically relevant biomarkers in 18 patients, including ESR1, BRAF, FGFR3, and BRCA2.“We are pleased to share data at ESMO that highlights our expanding diagnostics portfolio, which includes the newest version of our ultrasensitive Signatera Genome test,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera. “The incorporation of phased and structural variants results in the ability to detect ctDNA significantly below 1 part per 10 million and takes MRD sensitivity into a range we haven’t seen before.”

The 2026 ESMO program featuring Natera’s technologies includes:

October 23, 2026, 15:15 CET | Abstract 4258P
Presenter: Hideaki Bando, M.D., Ph.D.
Poster: Circulating tumor DNA (ctDNA)-informed risk prediction in breast (BC) and colorectal cancer (CRC) patients (pts): implications for solid organ transplant (SOT)

October 23, 2026, 15:15 CET | Abstract 4265P
Presenter: Luca Lazzari, Ph.D.
Poster: Genomic alterations and association with post-surgery circulating tumor DNA status in early-stage colon cancer

October 23, 2026, 15:15 CET | Abstract 4764P
Presenter: Yousef Zakharia, M.D.
Poster: Outcomes in patients with muscle-invasive bladder cancer with divergent differentiation or histologic subtypes from NIAGARA

October 23, 2026, 15:15 CET | Abstract 3633P
Presenter: Nicholas Bingham, BS
Poster: Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection

October 23, 2026, 16:15 CET | Abstract 542RO
Presenter: Yukinori Ozaki, M.D., Ph.D.
Rapid Oral: Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1

October 23, 2026, 15:15 CET | Abstract 4462P
Presenter: Benjamin O. Herzberg, M.D.
Poster: Genomic landscape of the SKI Complex in a large multi-cancer cohort of 260,000 tumors

October 23, 2026, 15:15 CET | Abstract 4276P
Presenter: Nicholas Hornstein, M.D., Ph.D.
Poster: Quantification of circulating tumor DNA (ctDNA) in patients using a multi-cancer, methylation-based assay for tissue-free treatment response monitoring (tf-TRM)

October 23, 2026, 15:15 CET | Abstract 4260P
Presenter: Jason A. Mouabbi, M.D.
Poster: Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors

October 23, 2026, 15:15 CET | Abstract 4417P
Presenter: Fizza Mughal, Ph.D.
Poster: Plasma whole-exome sequencing (pWES) reveals somatic landscape and clonal dynamics in metastatic urothelial carcinoma

October 24, 2026, 10:15 CET | Abstract 4741RO
Presenter: Matthew D. Galsky, M.D.
Rapid Oral: Exploratory analysis of molecular subtypes and association with treatment outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) from NIAGARA

October 24, 2026, 12:00 CET | Abstract 574P
Presenter: Adrianne L. Rolfes, M.D.
Poster: Neoadjuvant anti-PD1 without chemotherapy in early-stage luminal B breast cancer

October 24, 2026, 12:00 CET | Abstract 583P
Presenter: Teck Long King
Poster: ≥4 positive nodes identify a population enriched for ctDNA-guided adjuvant treatment escalation in ER+/HER2- early breast cancer

October 25, 2026, 12:00 CET | Abstract 808P
Presenter: Vicente Alonso-Orduna, M.D.
Poster: ctDNA negativity influences adjuvant treatment decisions: a paired counterfactual analysis from the SAGITTARIUS trial

October 25, 2026 | Abstract 870eP
Presenter: Carlo Federici, Ph.D.
e-Poster: Cost-effectiveness of a dynamic ctDNA-guided adjuvant strategy in stage II-III colon cancer, A SAGITTARIUS model-based analysis

October 25, 2026, 12:00 CET | Abstract 810P
Presenter: Stefano Tamberi, M.D., Ph.D.
Poster: ctDNA-guided adjuvant trials may miss the molecular residual disease (MRD) window: evidence of early attrition during trial allocation

October 25, 2026, 12:00 CET | Abstract 820P
Presenter: Benjamin Weinberg, M.D.
Poster: Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study

October 25, 2026, 12:00 CET | Abstract 3542P
Presenter: Torben Van Zijp
Poster: Organ preservation in rectal cancer after neoadjuvant radiotherapy, bevacizumab and atezolizumab: Translational analysis from the TARZAN study

October 25, 2026, 12:00 CET | Abstract 2901P
Presenter: Marco Gerlinger, M.D., FRCP
Poster: Clinical performance of the Signatera Genome assay in patients with localized gastroesophageal adenocarcinomas (GEA) treated with peri-operative FLOT and immunotherapy: ICONIC trial

October 26, 2026, 10:15 CET | Abstract 1770RO
Presenter: Kazuki Nozawa, M.D.
Rapid Oral: Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: Initial results from HER2-CR study

October 26, 2026, 10:15 CET | Abstract LBA62
Presenter: Jonathan Spicer, M.D., Ph.D.
Rapid Oral: ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE

References

William B, Galanina N, Iqbal M, et al. ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma. SOHO 2026 Annual Meeting, Houston, TX, September 9-12, 2026.About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261018851261/en/

NTRA weekly chart shows constructive long-term bullish trend
Moving-Average Support Defines Risk
Since support was found near the 20-day moving average during the prior minor pullback in August to a low of $316, it marks a key dynamic support area, with the potential of further downside if it is broken. In that scenario, key potential support is marked by the prior high and top of the more recent basing pattern at $343.18. But the next larger bullish trend is defined by dynamic support at the 50-day moving average, currently near $356 and rising.

If buyers can maintain control and underlying bullish momentum, a decisive breakout above the $437.41 high would be needed to signal an extension of the trend. However, as the short-term consolidation pattern further develops, it may produce other opportunities. Nonetheless, the upper boundary of a rising trend channel acted resistance near the recent high and may continue to constrain advances, even after a breakout.

Third Advance Could Be Developing
A decisive breakout above $437.41 would signal the potential start of a third leg higher in NTRA’s uptrend since its long-term base breakout in November 2024. Given the strength of the advance and the stock’s ability to consolidate while holding key support, the next leg higher could develop following a shorter consolidation period than the previous two advances.

If you’d like to know more about technical analysis and how traders use it, please visit our educational area.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.

TIME’s Best Inventions list, published annually, highlights the technologies and breakthroughs making the world better, smarter, and more innovative. To compile this year’s list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as healthcare and AI. TIME then evaluated each candidate on a number of key factors, including originality, efficacy, ambition, and impact.

Signatera, a personalized MRD test for patients diagnosed with cancer, was named to the list in the Medical & Healthcare category. This recognition comes as Signatera continues to advance as a foundational tool in modern cancer care, offering critical insights that inform care management for millions of patients.

Built from the unique genomic signature of each patient’s tumor, Signatera detects and quantifies tiny fragments of circulating tumor DNA (ctDNA) in the blood, providing ongoing monitoring for disease recurrence and response to treatment across cancer types. The test plays an important role in oncology drug development, helping pharmaceutical companies identify patients for clinical trials and accelerate the approval of novel therapies. It is the most widely adopted and extensively validated MRD test, supported by more than 200 peer-reviewed publications and used by more than 55% of oncologists in the U.S.

“One of the biggest problems in cancer care is knowing who needs additional therapy and who might safely avoid it,” said Steve Chapman, chief executive officer, Natera. “Signatera can help guide those challenging decisions, because it can detect disease recurrence in the blood up to two years in advance of imaging, giving patients and their doctors greater lead time and confidence. We are honored to receive this important recognition from TIME.”

Also in October 2026, Natera was named to Fortune’s Future 120. This list highlights companies across industries poised to define the next chapter of business and innovation. Together, these honors reflect Natera’s expanding role in precision medicine and the growing impact of the Signatera test across cancer care.

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261015268258/en/

Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

[url="]Natera, Inc.[/url] (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and [url="]TransCode Therapeutics, Inc[/url]. (Nasdaq: RNAZ),

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Natera's MCED assay analyzes cell-free DNA in.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, an aggressive form of skin cancer. The current standard of care for these patients is combination immunotherapy until clinical pro.

Natera, Inc. (NASDAQ:NTRA – Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $429.97 and last traded at $430.7150, with a volume of 2233 shares trading hands. The stock had previously closed at $425.64.

Analyst Upgrades and Downgrades A number of equities analysts recently commented on the stock. UBS Group lifted their price target on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Barclays reiterated an “overweight” rating and set a $340.00 target price on shares of Natera in a report on Friday, August 7th. Morgan Stanley reissued an “overweight” rating and issued a $355.00 price target on shares of Natera in a research report on Monday, August 10th. TD Cowen raised their target price on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Wells Fargo & Company raised their price target on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $341.55.

Read Our Latest Stock Report on NTRA

Natera Stock Performance The stock has a market cap of $59.79 billion, a PE ratio of -308.76 and a beta of 1.50. The company’s 50-day moving average price is $335.75 and its 200 day moving average price is $263.06. Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter in the prior year, the company earned ($0.74) earnings per share. The business’s quarterly revenue was up 37.7% on a year-over-year basis. As a group, equities research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Insider Transactions at Natera In related news, insider Solomon Moshkevich sold 15,160 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the completion of the sale, the insider owned 110,859 shares in the company, valued at $36,238,698.51. This trade represents a 12.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,580 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the completion of the transaction, the chief executive officer owned 102,973 shares of the company’s stock, valued at $26,162,350.11. The trade was a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 52,985 shares of company stock worth $16,119,137. 5.05% of the stock is owned by company insiders.

Institutional Trading of Natera Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Polaris Financial Partners acquired a new stake in shares of Natera in the third quarter worth $114,000. Versant Capital Management Inc raised its position in shares of Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after purchasing an additional 36 shares during the period. Burkett Financial Services LLC bought a new stake in shares of Natera during the third quarter valued at approximately $57,000. QRG Capital Management Inc. raised its position in shares of Natera by 32.7% during the 2nd quarter. QRG Capital Management Inc. now owns 19,488 shares of the medical research company’s stock worth $5,290,000 after buying an additional 4,797 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. grew its holdings in Natera by 9.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 4,921 shares of the medical research company’s stock worth $1,336,000 after acquiring an additional 429 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera (Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.

See Also Five stocks we like better than Natera Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion 3 Sectors Where Volatility Is Creating Entry Points, Not Exit Signals D-Wave’s Gate-Model Tech Notches a Major Milestone Vistra Stock Gains as Federal Funds Fuel Nuclear Power Expansion Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Chapman sold 1,273 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $413.31, for a total value of $526,143.63. Following the completion of the sale, the chief executive officer owned 96,926 shares in the company, valued at approximately $40,060,485.06. This trade represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total value of $545,041.02. On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total value of $819,415.64. On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60. On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10. Natera Price Performance Shares of NTRA stock opened at $410.35 on Monday. The firm has a market cap of $59.15 billion, a PE ratio of -301.73 and a beta of 1.50. Natera, Inc. has a 12 month low of $160.59 and a 12 month high of $427.47. The company’s fifty day simple moving average is $332.39 and its 200-day simple moving average is $261.45.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the business earned ($0.74) EPS. The company’s revenue was up 37.7% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.02 earnings per share for the current fiscal year. Institutional Trading of Natera Hedge funds have recently made changes to their positions in the business. Polaris Financial Partners acquired a new position in shares of Natera during the 3rd quarter worth approximately $114,000. Versant Capital Management Inc lifted its holdings in Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 36 shares during the last quarter. Burkett Financial Services LLC acquired a new stake in Natera during the 3rd quarter valued at $57,000. QRG Capital Management Inc. boosted its position in Natera by 32.7% during the second quarter. QRG Capital Management Inc. now owns 19,488 shares of the medical research company’s stock worth $5,290,000 after purchasing an additional 4,797 shares during the period. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of Natera by 9.6% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 4,921 shares of the medical research company’s stock valued at $1,336,000 after purchasing an additional 429 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth NTRA has been the subject of a number of analyst reports. Citigroup raised their price target on Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Sanford C. Bernstein initiated coverage on Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective on the stock. Rothschild & Co Redburn began coverage on shares of Natera in a research note on Tuesday, September 8th. They issued a “buy” rating and a $385.00 target price for the company. Leerink Partners set a $330.00 target price on shares of Natera in a report on Friday, August 7th. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $341.55.

Read Our Latest Report on Natera

Natera Company Profile (Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.

See Also Five stocks we like better than Natera Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam? The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

What happened Natera, Inc. (NASDAQ: NTRA) insider Solomon Moshkevich sold 3,000 shares on 2026-10-01 under a Rule 10b5-1 trading plan.

The Form 4 lists Moshkevich as PRESIDENT, CLINICALDIAGNOSTICS.

The trades were all in common stock and were split into three sales. The tranches were 200 shares at $411.62, 954 shares at $413.1066, and 1,846 shares at $415.0691.

Footnotes give transaction ranges of $411.55 to $411.69, $412.8350 to $413.3100, and $414.44 to $415.19 per share.

The filing puts the total value at about $1.24 million, and Moshkevich held 106,914 shares after the sale.

The filing was submitted by one reporting person, and the shares were held directly.

Key numbers Metric Latest Change Source Shares sold 3,000 shares SEC Form 4 Sale value about $1.24 million SEC Form 4 Shares held after sale 106,914 shares SEC Form 4 Sale price range from $411.62 to $415.07 per share SEC Form 4 Sale as a share of pre-sale holding 2.7% Calculated from SEC Form 4 Read more: Natera (NTRA) stock analysis and investment case

Why it matters OptimistFi's case is that Natera's value depends on proving that clinical adoption and reimbursement can keep scaling while test growth turns into durable cash generation.

This filing is mixed for that view because it shows a planned sale by a senior operator, but it also shows a continuing ownership stake.

The 3,000 shares were about 2.7% of the pre-sale holding, so the trade was a small slice of the position rather than a full reduction.

The filing says the sale was made under a Rule 10b5-1 plan adopted on November 26, 2024.

That timing means the trade schedule was set long before the 2026-10-01 sale, which limits how much investors can read into the transaction.

Because Moshkevich still held 106,914 shares, the report shows ongoing exposure to Natera's stock.

Even so, the report gives a fresh data point on insider activity for investors watching whether rapid test growth is translating into durable cash generation.

Browse: stock research on every company OptimistFi covers

What's next Natera's next quarterly report is the next scheduled test of the case.

Investors will watch whether the company keeps scaling clinical adoption and reimbursement and whether cash generation improves.

A stronger report would matter more than this planned sale, while weaker results would leave the filing's mixed read in place.

The Form 4 itself does not change the operating story, but the next report will show whether the business keeps moving toward the cash outcome in the investment case.

More from OptimistFi NTRA stock: the Natera thesis, its status and the next test to watch Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19% Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC Form 4 — Form 4 filed 2026-10-02 Calculated from SEC Form 4 — 3,000 shares were about 2.7% of the pre-sale holding Read the full OptimistFi thesis on Natera, Inc.: https://optimistfi.com/stocks/NTRA

See what would break the Natera, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full Natera, Inc. investment case, its status and the next test to watch live on the Natera, Inc. thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.

Key Takeaways Natera secured Japan PMDA approval for Signatera as a companion diagnostic in MIBC.The approval supports Signatera-guided adjuvant atezolizumab decisions after surgery.IMvigor011 data supported approval, with more than 20 Japanese sites in the Phase III trial. Natera (NTRA - Free Report) recently announced that its Signatera test received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) for use in muscle-invasive bladder cancer (MIBC). The approval supports Signatera-guided decisions for adjuvant atezolizumab (Tecentriq) treatment and marks the company’s second PMDA authorization for Signatera in three months. NTRA plans to commercially launch Signatera for MIBC in Japan in the first half of 2027.

Management stated that the company looks forward to launching its second Signatera MRD indication in Japan, providing patients with MIBC a diagnostic tool to guide treatment decisions during the first year after surgery. Natera highlighted its growing partnership with the Japanese oncology community, which has been actively adopting MRD in clinical trials and clinical practice.

Likely Trend of NTRA Stock Following the NewsFollowing the announcement, NTRA stock gained 5.5% at yesterday’s close. Year to date, shares of the company have rallied 70.6% compared with the industry’s 4.2% growth and the S&P 500’s 13% gain.

The PMDA approval may support broader adoption of Signatera in Japan’s MIBC treatment landscape and expand Natera’s international presence in MRD-guided oncology care. Greater adoption of MRD testing could also improve recurring testing volumes and deepen Natera’s competitive position in the rapidly developing precision oncology market.

NTRA currently has a market capitalization of $53.43 billion.

Image Source: Zacks Investment Research

More on the NewsThe regulatory approval was supported by data from the IMvigor011 randomized, double-blind Phase III clinical trial, which evaluated Signatera-guided adjuvant atezolizumab in patients with MIBC. The trial included more than 20 participating sites in Japan, providing Japanese clinicians with experience using Signatera-guided treatment in this setting.

The PMDA authorization follows Signatera’s approval in colorectal cancer in Japan in June 2026. It also follows the FDA approval of Signatera as a CDx for adjuvant atezolizumab in MIBC, along with the FDA approval of atezolizumab for the indication.

The National Comprehensive Cancer Network’s Clinical Practice Guidelines for Bladder Cancer recently issued a Category 1 recommendation for MRD-guided adjuvant atezolizumab. These regulatory and clinical developments could support the broader integration of MRD testing into bladder cancer treatment decisions.

Bladder cancer affects more than 34,000 people annually in Japan, with approximately 20-25% of newly diagnosed cases classified as MIBC. The higher recurrence risk and treatment complexity associated with MIBC underscore the need for precision diagnostic tools that can help clinicians individualize adjuvant treatment decisions.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease (MRD) testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsLast month, Natera announced a national partnership with Susan G. Komen to advance breast cancer awareness, education and research. The collaboration will expand understanding of MRD testing and support patient education initiatives. Natera will also serve as the 2026 Premier National Series Sponsor of Komen’s Race for the Cure and MORE THAN PINK Walk events.

Natera announced a collaboration with Angiex, Inc. to assess treatment response to AGX101, an investigational nuclear-delivered antibody-drug conjugate (ND-ADC), using its Signatera test. The Phase 1 trial is evaluating AGX101 in patients with unresectable, locally advanced or metastatic solid tumors.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.

Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC). This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially.

Natera, Inc. (NTRA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:45 AM EDT

Company Participants

Steve Chapman - CEO & Director
Mike Brophy - Chief Financial Officer

Conference Call Participants

Kallum Titchmarsh - Morgan Stanley, Research Division

Presentation

Kallum Titchmarsh
Morgan Stanley, Research Division

Okay. I know we're a couple of minutes away, but I think we can get started given there's a lot to cover. I'm Kallum Titchmarsh, the life sciences analyst here at Morgan Stanley. Really pleased today to be joined by the team at Natera. We have Steve Chapman, CEO; and Mike Brophy, CFO. Thanks, guys, for being here.

Steve Chapman
CEO & Director

Yes, cheers. Thanks for having us.

Question-and-Answer Session

Kallum Titchmarsh
Morgan Stanley, Research Division

Thank you. Just before we get started, for all disclosures relating to this presentation, please see morganstanley.com/researchdisclosures. Now the fun stuff's out of the way, maybe we can start on that Q2. Obviously, we're expecting strong numbers, but I think even the Q2 came comfortably above our expectations, just under 40% year-over-year sales growth, record sequential Signatera tests and then a healthy raise on the back of that. Maybe just stepping back, how has your confidence in the business evolved year-to-date? And where do you perhaps think investors may still be underestimating that durability of growth?

Steve Chapman
CEO & Director

Yes. So I'd say, obviously, very strong quarter and year-to-date. We've had multiple revenue raises. We've seen acceleration in Signatera volume and really just strength across the business overall. I think in Q2, we had 34,000 quarter-over-quarter growth, which was just an all-time record for Signatera, super exciting.

I would say the area that I think is maybe most underappreciated is just how big the MRD market opportunity is. And when we start to look drilling into

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations.

A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with resected stage 1-3 non-small cell lung cancer (NSCLC) spanned an observation period from 2016 to 2025. Signatera MRD detection was evaluated in the early post-surgical window and throughout surveillance, with the following key findings:

Early post-surgical Signatera-status was strongly prognostic of recurrence-free survival. Signatera-positivity in the early post-surgical window (7–90 days after surgery) was associated with significantly worse recurrence-free survival (RFS), with a 25% higher absolute 3-year RFS for Signatera-negative patients.Signatera-positive patients had approximately 5X the risk of recurrence or death during surveillance.Findings were consistent across both the primary surgical and perioperative cohorts, supporting broad applicability of Signatera monitoring across resected stage 1-3 NSCLC.“One of the pressing challenges in early-stage lung cancer is knowing which patients are truly at risk of recurrence and our standard clinical tools don't reliably give us that answer,” said Charu Aggarwal, M.D., MPH, FASCO, the Leslye Heisler Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine and principal investigator of the study. “This dataset showed, across more than 1,100 patients, that Signatera MRD status, in the early post-surgical window and throughout surveillance, is a powerful and consistent predictor of recurrence-free and overall survival. That kind of evidence, at this scale, can meaningfully change how we think about adjuvant treatment decisions in lung cancer.”

“Lung cancer touches more patients globally than any other cancer, and WCLC is a powerful reminder of the collective commitment to doing better for them,” said Caitlin Schonewolf, M.D., MS, senior medical director, oncology, Natera. “Earlier and more precise answers can mean more time and better quality of life for patients with lung cancer.”

Full list of presentations at WCLC 2026 included:

Abstract P2.192
Presenter: Deborah Doroshow, M.D., Ph.D.
Poster: ctDNA After Definitive Therapy ± Immunotherapy and Association with Survival Outcomes in Locally Advanced Unresectable NSCLC

Abstract P2.200
Presenter: Seohee Shim, M.D.
Poster: ctDNA-based Molecular Residual Disease as a Predictive Biomarker for Treatment Stratification in Unresectable Stage 3 NSCLC

Abstract MO05.07
Presenter: David Gandara, M.D.
Mini Oral: KRAS G12C Predicts Superior Outcomes with 1L Cemiplimab for Non-Squamous aNSCLC With PD-L1 ≥ 50%: Data From EMPOWER-Lung 1

Abstract MO11.09
Presenter: Charu Aggarwal, M.D., MPH, FASCO
Mini Oral: Post-Surgical Molecular Residual Disease Detection, Adjuvant Treatment Patterns, and Overall Survival in Resected Stage 1-3 NSCLC

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260918220514/en/

Stanley Druckenmiller has quite a long and distinguished career as an investor. Much of this has to do with high-risk bets that have paid off enormously, such as when he and his boss, George Soros at Quantum Fund, shorted the U.K. pound for a handsome profit of what was reported to be around $1 billion.

For that reason, the trades Druckenmiller makes with his Duquesne family office matter, and his picks are taken seriously. One of the more intriguing ones is Duquesne's largest holding currently -- and for eight quarters now. It's not a famous name; rather, it's a next-generation healthcare diagnostics company that was once something of a sleeper. Here's a bit more about it.

Image source: Getty Images.

Doing it with diagnostics This huge bet on the future is Natera (NTRA +0.78%), a medical diagnostics company that uses unique, state-of-the-art technology to evaluate a patient's blood sample. Natera isn't the only business providing these liquid biopsies, as they're known, but its personalized, tumor-informed approach makes it a best-in-class screener in numerous use cases.

The major one is oncology, which is hardly surprising given the prevalence of cancer. Natera has a set of tests for this, led by Signatera, a highly personalized one constructed from the patient's tumor profile. With this, it detects circulating tumor DNA in the blood. To say this is useful in cancer detection is an understatement, so it's hardly surprising that Natera processed roughly 296,700 oncology tests in the company's second quarter. That was up a highly impressive 57% year over year.

Oncology screening isn't the company's only revenue driver. Zooming out a bit, its tally of completed tests rose by more than 22% that quarter, crossing the 1 million mark.

Natera's financials have followed suit. Its second-quarter revenue, overwhelmingly derived from testing services, zoomed 38% higher. Even though there was a leap in research and development expenses -- usually a good sign for an ambitious healthcare company -- its net loss narrowed admirably, from nearly $101 million in the year-ago quarter to under $67 million.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

0.78

%) $

2.56

Current Price

$

331.49

Paths for growth Natera still has strong growth potential if it simply expands the scope and reach of its tests, both here and abroad. It's already traveling down that path: For example, in late June, it earned approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for Signatera to screen for colorectal cancer.

Natera's diagnostics are also seeing increased take-up from expanded Medicare local coverage determinations (decisions made by regional administrative contractors of the program). These have been an important factor in the increased overall take-up of the tests and are sure to continue to be so.

One major concern for almost any up-and-coming healthcare company is its runway. In other words, how long can it continue operating while incurring losses? Natera looks good: At the end of June, it had nearly $1.1 billion in its coffers, and that cash position had actually grown slightly over each of the preceding four quarters. And management is guiding for positive free cash flow for the entirety of 2026. This well of greenbacks won't go dry anytime soon.

At the moment, according to data compiled by Yahoo! Finance, 19 analysts track the stock (a testament to its increasing popularity). These pundits foresee Natera continuing to reduce its bottom-line losses; their collective estimate for full-year 2026's deficit is $1.39 per share and for 2027's is a wafer-thin $0.09 per share. Either would be a marked improvement over last year's $1.52-per-share loss.

There will also be notable revenue gains. The consensus prognosticator projection for annual take is $2.91 billion this year, up almost 26% from 2025. In 2027, this should again bounce higher, to nearly $3.5 billion.

A negative or two to consider Natera isn't a picture-perfect stock; if it were, Druckenmiller probably would have bought and exited from it years ago. While its bottom-line losses are narrowing, they're still considerable and persistent, and expenses will always be high for the company.

It's also getting famous, thanks in no small part to the well-respected investor, and its share price growth reflects this -- up 87% over the last year alone, compared to the S&P 500 index's 17% gain. This makes its valuations extremely lofty, with a price-to-sales ratio of almost 17.

So should you pull a Druckenmiller and buy Natera? I feel the stock has a very high ceiling, since it has few (if any) peers, and the more effective a diagnostic, the greater the demand will be. Even with that price run-up, I think the stock has plenty more room to rise, and I consider Natera a fine buy.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.

Brandywine Managers LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 14,588 shares of the medical research company’s stock, valued at approximately $3,960,000. Natera comprises about 2.0% of Brandywine Managers LLC’s investment portfolio, making the stock its 5th largest holding.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. BlackRock Inc. bought a new position in Natera in the second quarter valued at about $2,962,770,000. Wellington Management Group LLP raised its position in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp boosted its stake in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Finally, Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera In other news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roelof Botha sold 78,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 177,955 shares of company stock worth $40,704,193. Company insiders own 5.05% of the company’s stock.

Natera Price Performance Shares of NTRA opened at $327.72 on Tuesday. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $333.56. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The business has a 50-day moving average of $276.45 and a 200-day moving average of $230.09. Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.74) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.02 EPS for the current year.

Analyst Ratings Changes NTRA has been the subject of several recent research reports. Leerink Partners set a $330.00 price objective on Natera in a research note on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. BTIG Research boosted their target price on shares of Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Finally, Citigroup raised their price target on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Check Out Our Latest Stock Analysis on NTRA

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

See Also Five stocks we like better than Natera Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Callan Family Office LLC bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 3,582 shares of the medical research company’s stock, valued at approximately $972,000.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Natera during the 2nd quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc bought a new stake in Natera in the second quarter valued at approximately $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the second quarter valued at approximately $1,537,000. UBS Group AG increased its stake in shares of Natera by 19.4% in the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares during the period. Finally, Fifth Third Bancorp increased its stake in shares of Natera by 3,373.1% in the first quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock worth $2,251,000 after buying an additional 10,929 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera In related news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the completion of the transaction, the chief financial officer directly owned 51,637 shares of the company’s stock, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 177,955 shares of company stock worth $40,704,193. Corporate insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades Several equities analysts have recently commented on the stock. Citigroup upped their price objective on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Leerink Partners set a $330.00 price target on Natera in a research report on Friday, August 7th. Wells Fargo & Company increased their price objective on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Guggenheim lifted their price objective on Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Evercore restated an “outperform” rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $319.38. Get Our Latest Research Report on NTRA

Natera Stock Performance NTRA stock opened at $327.72 on Tuesday. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $333.56. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The business’s 50 day moving average price is $276.45 and its two-hundred day moving average price is $230.09.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter last year, the business posted ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. Sell-side analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Further Reading Five stocks we like better than Natera Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

ADAR1 Capital Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 2,147 shares of the medical research company’s stock, valued at approximately $583,000.

A number of other large investors also recently made changes to their positions in NTRA. Hsbc Holdings PLC acquired a new position in shares of Natera in the 2nd quarter worth $23,551,000. EFG International AG acquired a new position in shares of Natera during the second quarter worth approximately $13,263,000. Canada Pension Plan Investment Board acquired a new stake in shares of Natera during the 2nd quarter worth approximately $33,741,000. Castleark Management LLC bought a new position in shares of Natera during the 2nd quarter worth about $755,000. Finally, Legal & General Group Plc bought a new position in shares of Natera during the 2nd quarter worth approximately $150,143,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research firms recently weighed in on NTRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Wells Fargo & Company increased their price objective on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Guggenheim increased their price objective on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Leerink Partners set a $330.00 price objective on Natera in a report on Friday, August 7th. Finally, Barclays restated an “overweight” rating and set a $340.00 price objective on shares of Natera in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $319.38.

Get Our Latest Analysis on NTRA Natera Trading Up 0.5% Natera stock opened at $338.45 on Thursday. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $340.96. The firm’s fifty day moving average price is $281.03 and its two-hundred day moving average price is $232.01. The firm has a market capitalization of $48.78 billion, a price-to-earnings ratio of -248.86 and a beta of 1.51.

Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business’s revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.74) earnings per share. On average, research analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.

Insider Buying and Selling at Natera In other news, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the sale, the chief financial officer directly owned 51,637 shares in the company, valued at approximately $14,159,898.14. This represents a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 177,955 shares of company stock worth $40,704,193. Corporate insiders own 5.05% of the company’s stock.

Natera Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Recommended Stories Five stocks we like better than Natera Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks? Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.

Some investors throw money at lots of stocks and hope that enough become winners to offset the inevitable losers. That isn't the approach Stanley Druckenmiller takes. The billionaire only invests in high-conviction stocks after a thorough analysis.

Druckenmiller's Duquesne Family Office currently owns 90 stocks. But 16.6% of the portfolio is invested in only one stock -- Natera (NTRA -3.67%). This genomics stock has skyrocketed roughly 80% since its year-to-date low on May 15, 2026. Is Natera still a buy?

Stanley Druckenmiller. Image source: Getty Images.

Behind Druckenmiller's big bet on Natera Druckenmiller first initiated a position in Natera in the third quarter of 2022. He has added more shares than he's sold since then, most recently increasing his family office's position in the company by 4% in the second quarter of 2026.

Natera's Q2 update earlier this month underscored why the billionaire likes this stock so much. The company's revenue jumped 37.7% year over year to $752.8 million. Natera processed more than 1.04 million tests in Q2, up 22.4% from the prior year period.

The big growth driver for Natera is oncology. The company handled around 238,000 molecular residual disease (MRD) oncology tests in Q2, a 56% year-over-year increase. This also reflected Natera's largest sequential increase so far.

Much of this growth is due to Signatera, a personalized blood test that detects circulating tumor DNA from tumor cells. In May 2026, Signatera became the first companion diagnostic for blood-based MRD detection of bladder cancer approved in the U.S.

More growth should be on the way. Natera won Japanese regulatory approval of Signatera in colorectal cancer testing in June. In July, the company secured the first European Union In Vitro Diagnostic Regulation (IVDR) certification for a personalized MRD test for solid tumors. Natera also is moving forward with plans to file for Japanese approval of Signatera as a companion diagnostic in muscle-invasive bladder cancer.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

-3.67

%) $

-12.44

Current Price

$

326.26

To buy or not to buy? No one should buy a stock solely because a billionaire investor bought it, even when that investor has been as successful as Druckenmiller. Importantly, Druckenmiller accumulated most of his position in Natera at a discount to today's price.

Valuation is the main knock against the stock. Natera remains unprofitable, so earnings-based valuation metrics aren't relevant. However, the stock trades at roughly 17 times trailing 12-month sales -- a steep multiple no matter how you look at it.

However, Natera continues to generate strong growth. I think the stock could be a winner for long-term investors, but the easy money has already been made.

Bank of New York Mellon Corp acquired a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 549,927 shares of the medical research company’s stock, valued at approximately $149,278,000. Bank of New York Mellon Corp owned about 0.38% of Natera at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTRA. JPMorgan Chase & Co. increased its position in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp grew its position in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the last quarter. Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after buying an additional 11,689 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades A number of research analysts have recently weighed in on NTRA shares. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. Citigroup upped their price objective on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Stephens boosted their target price on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Read Our Latest Research Report on NTRA Insider Activity In other news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 181,045 shares of company stock worth $41,330,968. Corporate insiders own 5.05% of the company’s stock.

Natera Price Performance NASDAQ NTRA opened at $332.03 on Monday. The firm’s 50 day moving average is $274.24 and its 200-day moving average is $229.38. The company has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56.

Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

See Also Five stocks we like better than Natera VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

During his three decades as manager of the hedge fund Duquesne Capital, Stanley Druckenmiller averaged annual returns of around 30%, beating not just the S&P 500 but also many other major hedge funds. Druckenmiller wound down his fund in 2010, converting it into a family office.This left him still highly active in the investing game, but just with his own money.

Investors can keep track of the Duquesne Family Office's positions by looking up its latest 13F filings with the Securities and Exchange Commission (SEC). Per the latest filing, submitted Aug. 14, for the quarter ended June 30, 2026, Duquesne's largest position is in Natera (NTRA +1.92%). This position, worth around $865 million, makes up 16.6% of Duquesne's overall portfolio. While the family office has continued to build up a stake in the diagnostics company, much of its value is the result of the stock's big run-up thus far in 2026.

The question now is whether more upside remains for shares, or if the stock, after its strong extended run, is at risk of an extended pullback.

Stanley Druckenmiller. Image source: Getty Images.

Natera and its recent hot run Since the start of the year, Natera has rallied by over 37%. For comparison, the S&P 500 is up just a relatively smaller 13.9% over this same time frame. Cutting-edge healthcare stocks can make volatile moves, in either direction, and that's what has happened with Natera, following a spate of positive news.

Earlier in the year, Natera shares traded sideways, even as investors remained appreciative of the company's unique strengths. This includes its dominant share of the minimal residual disease (MRD) testing market, a key segment given the strong demand for products that help detect cancer recurrence. Still, despite such strengths, valuation worries became the greater concern.

However, following two key developments, valuation worries have moved to the back burner. First, in June, shares rallied on news that Natera had received regulatory approval in Japan for its Signatera product for colorectal cancer testing. Second, and more importantly, investors reacted very positively to Natera's latest quarterly results.

As insiders sell, should you keep following Druckenmiller's lead? On Aug. 6, Natera released results for the 2026 second quarter. During this period, revenue increased 37.7% year over year, from $546.6 million to $752.8 million. The company also reported a more than 100-basis-point improvement in gross margins, as well as further progress in reaching profitability. Management also raised full-year revenue guidance, from $2.85 billion to $2.91 billion.

Today's Change

(

1.92

%) $

6.23

Current Price

$

331.30

Alongside promising financials, Natera also keeps making progress in expanding the label for its products. After the aforementioned win in Japan, the company is now seeking regulatory approval for Signatera's use as a test for muscle-invasive bladder cancer.

With the company still unprofitable, and shares trading for 16 times sales, valuation remains sky-high among medical device stocks. Near-term profit-taking, or worse, investor disappointment over further near-term developments, could lead to another sharp pullback in shares. It also doesn't help that insiders continue to sell shares, showing little interest in increasing their own personal positions.

Still, it's likely not irrational exuberance that's leading Druckenmiller to keep buying. Long-term forecasts call for double-digit revenue growth to persist, with earnings turning positive by 2028. Wait for further weakness before buying, but the long-term bull case remains intact for now.

Key Takeaways Institutional heavyweights are betting on the AI ecosystem.SpaceX is a top addition among many big money managers.Cerebras is another core top holding for many top investors. 13F is a quarterly report that institutional investors managing over $100 million must disclose with the SEC. 13Fs can provide valuable insight into America’s top investors. Below are the 5 most important 13Fs to watch:

NVIDIANVIDIA is the largest company in the world by market cap ($5 trillion). Beyond its size, the company’s investments are worth watching because no other company on the planet has its finger on the pulse of the AI boom like NVIDIA and its iconic CEO Jensen Huang. At a 44% weighting, Intel ((INTC - Free Report) ) remains its largest position. Earlier this year, NVIDIA made a $5 billion investment in Intel common stock in return for a manufacturing and data center collaboration. Meanwhile, SpaceX ((SPCX - Free Report) ) was NVIDIA’s largest addition and comprises 30.94% of the portfolio. NVIDIA is also betting big on leading neocloud stocks like CoreWeave (CRWV) and Nebius (NBIS) (NVIDIA has partnerships with both).

Image Source: Zacks Investment Research

Brad Gerstner, Altimeter CapitalBrad Gerstner is one of America’s leading venture capitalists, tech entrepreneurs, and hedge fund managers. Gerstner is best-known for his early bets in Snowflake ((SNOW - Free Report) ), Google ((GOOGL - Free Report) ), and Meta Platforms ((META - Free Report) ). His top two positions are NVDA ((NVDA - Free Report) ) (19.16%) and Cerebras (CBRS) (16.24%). Like many other leading tech managers, Gerstner’s top buys in the second quarter were SpaceX, Micron ((MU - Free Report) ), and CRBS. CRBS is currently building the right side of an IPO base structure.

Image Source: TradingView

Lone Pine CapitalLone Pine Capital is on our list because of its tremendous outperformance. As of June, Lone Pine was up 43%. Lone Pine’s largest position and one it added to is Nebius Group. It is also bullish on other leading AI-related names like ASML Holding ((ASML - Free Report) ) and Seagate Technologies ((STX - Free Report) ).

Image Source: Zacks Investment Research

Stanley DruckenmillerStanley Druckenmiller is a legendary investor best-known for managing money for more than 30 years without a single losing year. Druckenmiller’s largest holding is Natera ((NTRA - Free Report) ), a medical devices company. Some of Druckenmiller’s top buys include Magnificent 7 names such as Google and Amazon ((AMZN - Free Report) ).

Gavin Baker, AtreidesGavin Baker is a tech specialist who is best-known for his early investment in NVIDIA and other tech compounders. Baker is betting big on AI with top positions in Micron, Cerebras, and Astera Labs ((ALAB - Free Report) ).

Image Source: Zacks Investment Research

Bottom Line

Quarterly 13F disclosures offer individual investors an irreplaceable window into the playbooks of market-moving institutions. Top bets this quarter include SpaceX, recent IPOs, and AI infrastructure stocks.

3 Under-the-Radar Healthcare CompaniesNatera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.

Speaking at the Canaccord Genuity Growth Conference, Brophy said Natera raised its outlook following a quarter in which volume performance was broad-based. He described organ health momentum as “very strong” and said women’s health posted high-single-digit year-over-year growth despite typically experiencing seasonal sequential declines.

Get Natera alerts:

Women’s Health Momentum and Product Updates
Myriad Genetics Sees Stock Surge with Hereditary Cancer TestsBrophy attributed part of the women’s health performance to uptake of Natera’s Fetal Focus offering, which launched several quarters ago and continued to gain traction through the second quarter. He also highlighted the June launch of a new version of the Panorama non-invasive prenatal testing assay.

The updated Panorama test is designed to offer greater sensitivity, particularly in cases with low fetal fraction, an area that Brophy said has historically been challenging for non-invasive prenatal testing. Because the launch occurred in early June, he said it was not a significant driver of second-quarter results but could support women’s health performance during the remainder of the year.

While Brophy characterized the quarter as exceptional, he said his typical framework for women’s health is mid-single-digit volume growth, with the opportunity for faster revenue growth if Natera can increase reimbursement realization for covered services.

Record Signatera Volumes
The company’s oncology business, led by its Signatera molecular residual disease and recurrence-monitoring test, reached more than 280,000 units during the quarter. Brophy said the company added approximately 34,000 units sequentially, compared with a prior quarterly record increase of about 25,000 units.

He noted that first-quarter Signatera volumes were somewhat affected by weather-related disruptions. Natera estimates that roughly 2,000 to 4,000 units that otherwise may have been received in the first quarter arrived later, contributing to the magnitude of the second-quarter sequential increase. Even excluding that effect, Brophy called the quarter an “absolute blowout.”

He cited several drivers of Signatera’s growth:

Continued generation of clinical outcomes data for Signatera and molecular residual disease testing.
FDA approval related to Signatera’s use in muscle-invasive bladder cancer.
Inclusion in National Comprehensive Cancer Network guidelines for muscle-invasive bladder cancer in June.
The full operational impact of a commercial expansion completed around April.

Brophy said newer offerings, including Genome and Latitude, accounted for only a small portion of total Signatera volume. However, he said their availability broadens the company’s product menu and may enhance Signatera’s positioning with physicians.

Coverage, International Expansion and Laboratory Investment
Natera expects to continue pursuing reimbursement coverage on a tumor-type-by-tumor-type basis, Brophy said. He described the company’s interactions with MolDX, Medicare’s molecular diagnostic services program, as positive and said Natera has now achieved coverage across much of the critical mass of common tumor types. The company is now working on additional, less common cancers, he said.

In Japan, Natera has received PMDA approval for Signatera and has submitted for bladder cancer coverage following its approval in colorectal cancer. Brophy said the company remains on track for an early 2027 Japanese launch. The next steps include discussions with Japanese agencies regarding the number of reimbursed testing time points and pricing, which he expects to be addressed in the second half.

The company is also expanding laboratory capacity. Brophy said Natera’s Austin, Texas, laboratory is expected to become the world’s largest genomics laboratory once its current expansion is completed. First-half capital expenditures increased to approximately $85 million from about $45 million in the prior-year period. He said the elevated spending level is not expected to represent ongoing maintenance capital expenditures, which he estimated at closer to $60 million annually.

Early Cancer Detection Investment
Brophy said Natera remains ambitious in early cancer detection, where its FIND-CRC study is approaching enrollment completion at up to 40,000 patients. He emphasized the expense and complexity of bringing a blood-based early cancer detection assay to market, estimating that a company may need to spend roughly $500 million before selling its first test when clinical development and regulatory work are included.

Rather than immediately building a large commercial team, Brophy said Natera expects to use a phased approach, deploying an initial group of sales representatives in selected geographies and expanding based on early results and returns on invested capital.

He acknowledged that early cancer detection spending is currently weighing on the company’s overall profit profile because the program is generating operating expenses without revenue or gross profit. Still, he said Natera is seeing losses narrow while continuing to invest in research and development, Signatera clinical studies and commercial growth initiatives.

Looking internationally, Brophy said Natera sees significant demand for Signatera in Europe following IVDR approval. He said reimbursement opportunities will need to be evaluated country by country and use case by use case, while noting that the company is conducting clinical studies in Europe, including CIRCULATE-France.

About Natera (NASDAQ:NTRA)Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Natera Right Now?Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report